Exela Pharma Sciences

Executive Summary

Exela Pharma Sciences is a privately held, integrated specialty pharmaceutical company based in Lenoir, North Carolina, founded in 2005. The company develops and manufactures proprietary and generic sterile injectable products, operating through two business units: Finished Drug Products and Contract Development and Manufacturing Organization (CDMO) services. Exela focuses on addressing healthcare provider needs, improving patient experience, and alleviating drug shortages in the sterile injectable market. As a private company with no public ticker, Exela's financials are not disclosed, but its business model targets both high-demand generic injectables and customized CDMO solutions for partners. The company's ability to navigate regulatory complexities and maintain reliable supply positions it as a key player in the fragmented sterile injectable space, though its lack of transparency and limited public information constrain investor visibility.

Upcoming Catalysts (preview)

• TBDFDA Approval of Key Generic Injectable50% success
• TBDExpansion of CDMO Contract with Major Pharma40% success
• TBDLaunch of Proprietary Product Addressing Drug Shortage30% success